During the last trading session, 1.16 million shares of Orchard Therapeutics plc (NASDAQ: ORTX) were traded. More recently, the company’s stock price was $ 3.32, and it has changed about $ 0.05 or 1.53% since the last close, bringing the company’s market valuation to $ 404.97 million. ORTX is currently trading below its 52 week high of $ 9.08, offering nearly -173.49% on that amount. The stock price’s 52-week low was $ 3.22, indicating that the present value has risen 3.01% since then. We note from Orchard Therapeutics plc’s average daily trading volume that its 10-day average is 0.69 million shares, with the 3-month average reaching 496.29,000.
Orchard Therapeutics plc stock received a consensus buy recommendation rating, based on an average score of 1.60. If we take it even further, the data shows that 0 in 10 analysts rate the stock as a sell; another 0 rates him as overweight. Of the rest, 0 recommended ORTX as a Hold, while 10 viewed it as a buy and 0 rated it as underweight. Orchard Therapeutics plc is expected to report earnings per share of $ -0.33 for the current quarter.
Instantly ORTX showed a green trend with a performance of 1.53% at the end of the last trade. The performance of the last five days has remained in the red. Rising from weekly highs of 3.73 on Tuesday 7/20/21 increased the daily share price by 10.99%. Shares of the company are currently down -23.15% year-to-date, but still down -8.79% in the past five days. On the other hand, Orchard Therapeutics plc (NASDAQ: ORTX) is down -31.40% over the 30-day period. We can see from the shorts that 4.83 million shares were sold on a short interest coverage period of 11.47 day (s).
The consensus price target assigned by Wall Street analysts is $ 12.60, which means bulls need to raise their stock price 73.65% from its current value. Analysts’ projections indicate that ORTX should reach a low of $ 8.00 and a high of $ 16.00. For the stock price to reach the expected high, the stock would have to plunge -381.93% from its current level, while the stock would have to slump -140.96% from its current level. current to reach the expected low.
Orchard Therapeutics plc (ORTX) estimates and forecasts
Orchard Therapeutics plc share prices perform particularly well compared to other companies in the same industry. As the statistics show, the company’s shares have fallen -51.95% in the past six months and at an annual growth rate of 12.42% well above the industry average of 8.90%. Additionally, analysts have decided to postpone their revenue estimates for fiscal 2021. Rating agencies predict that it will gain 31.20% in revenue this quarter and report a decline of -65.00% in the quarter. next quarter. The year-over-year growth rate is expected to be 90.00%, up from the previous year.
Consensus estimates provided by 8 financial analysts predict that the company will generate an average of $ 260,000 in revenue for the current quarter. 8 analysts expect Orchard Therapeutics plc to achieve sales of $ 1.4 million for the quarter ending September 2021. The company’s sales for the same quarters a year ago were respectively of $ 597,000 and $ 110,000. Analysts expect the company’s current quarter sales to fall, forecast to -56.40%. Forecasts for the next quarter are for sales growth of 1,172.70%.
Orchard Therapeutics plc’s next quarterly earnings report is expected to be released around August 4 and 9.
Principal holders of Orchard Therapeutics plc (NASDAQ: ORTX)
Looking at the major shareholders, it appears that insiders own 0.12% of the shares of Orchard Therapeutics plc, and 68.91% of them are held by institutional investors. The stock currently has a free float of 68.99%. Orchard Therapeutics plc shares are held by 105 institutions, with RA Capital Management, LP being the largest institutional investor. As of March 30, 2021, she held 9.95% of the shares, or approximately 12.32 million shares valued at $ 89.41 million.
Artisan Partners Limited Partnership, with 8.60% or 10.64 million shares valued at $ 77.27 million as of March 30, 2021, holds the second highest percentage of shares outstanding.
>> 7 top choices for the post-pandemic economy
Artisan Small Cap Fund and JP Morgan Small Cap Growth Fund were the two largest mutual funds as of March 30, 2021. The former held 4.97 million shares valued at $ 36.08 million, or 4 .02% of all shares outstanding. On the other hand, JP Morgan Small Cap Growth Fund held approximately 1.61 million shares valued at approximately $ 11.66 million, which is approximately 1.30% of the total shares outstanding.